UPL Ltd. (NSE: UPL & BSE: 512070) is a global provider of sustainable agriculture products & solutions, with annual revenue exceeding $5 billion. As one of the top 5 agriculture solutions companies worldwide, our robust portfolio consists of biologicals and traditional crop protection solutions with more than 13,600 registrations. With a presence in more than 130 countries and more than 10,000 colleagues globally, we reach more than 90% of the world’s food basket. For more information about our integrated portfolio of solutions across the food value chain including seeds, post-harvest, as well as physical and digital services, please visit upl-ltd.com.

At Piedmont Chemical Industries, we’ve used the same formula for success for 80 years: focus on developing and manufacturing high quality textile and specialty chemicals that provide innovative solutions to our customers’ problems and maintaining the best customer support and service in the industry. Since our beginning in 1938, Piedmont has evolved into 5 different production sites in the Southeast offering a wide range of manufacturing capabilities. Family is important to us at Piedmont, and we’re proud that we remain owned and operated by the family of our founder.

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Marken is the clinical and advanced therapy subsidiary of UPS Healthcare. With Marken, Polar Speed and BOMI Group included, the UPS Healthcare network consists of 200+ locations worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 60 locations worldwide, while maintaining the leading position for cell and gene therapy services, direct-to-patient and home healthcare services, biological sample shipments and biological kit production. Marken’s dedicated 2,600+ staff members manage 180,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries and territories and have orchestrated 16,000+ home healthcare visits. Additional services such as ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry. Delivering What Matters From Clinical to Commercial.

Jowat SE with headquarters in Detmold is one of the leading suppliers of industrial adhesives. These are mainly used in woodworking and furniture manufacture, in the paper and packaging industry, for graphic arts, in the textile, automotive as well as in the electrical industry. The company was founded in 1919 and has manufacturing sites in Germany in Detmold and Elsteraue, plus three other producing subsidiaries, Jowat Corporation in the USA, Jowat Swiss AG and the Jowat Manufacturing in Malaysia. The supplier of all adhesive groups is manufacturing over 100,000 tons of adhesives per year, with around 1200 employees. A global sales structure with 23 Jowat sales organisations plus partner companies is guaranteeing local service with close customer contact. Imprint: Jowat SE Ernst-Hilker-Straße 10 - 14 32758 Detmold Phone: +49 (0) 5231 749-0 E-Mail: [email protected] Data privacy: https://www.jowat.com/en/data-protection/

Engineered to perform Qualicaps® is a global manufacturer of empty pharmaceutical capsules and pharmaceutical processing equipment. With more than 100 years of experience, Qualicaps is a leader in innovation in both Quali-G™ (gelatin) and Quali-V® (hypromellose) capsules, and offers a proprietary product line of pharmaceutical equipment, including capsule filling, band-sealing and inspection machinery. For more information visit www.qualicaps.com.